Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-02
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 642
- Registration Number
- NCT00911547
Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 4748
- Registration Number
- NCT00909389
Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 3806
- Registration Number
- NCT00903721
Treatment of Multiple Attacks of Acute Migraine (0462-025)
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 473
- Registration Number
- NCT00899379
Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1268
- Registration Number
- NCT00898677
MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 933
- Registration Number
- NCT00897104
MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1473
- Registration Number
- NCT00897949
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 109
- Registration Number
- NCT00894556
An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 174
- Registration Number
- NCT00878462
Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 125
- Registration Number
- NCT00871351
© Copyright 2024. All Rights Reserved by MedPath